Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CADENCE

Financiado

Cerrado

Catalytic Dual Function Devices Against Cancer

Despite intense research efforts in almost every branch of the natural sciences, cancer continues to be one of the leading causes of death worldwide. It is thus remarkable that little or no therapeutic use has been made of a whole... ver más

31/08/2023

UNIZAR

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSIDAD DE ZARAGOZA. OFICINA DE TRANSFERE... No se ha especificado una descripción o un objeto social para esta compañía.

Sin perfil tecnológico

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

ERC-2016-ADG: ERC Advanced Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIZAR

2.48M€ | Lider

COMERSIM

201.35K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Cat4CanCenter Catalysis for Cancer Treatment. 11M€ Cerrado

PID2019-109111RB-I00 TRANSFORMACIONES CATALITICAS DE SUSTRATOS METALICOS Y SUS AP... 103K€ Cerrado

RTI2018-100709-B-C21 NUEVOS METALOFARMACOS DISEÑADOS PARA INCREMENTAR LA SELECTIV... 108K€ Cerrado

PID2020-116460RB-I00 SISTEMAS QUIMICOS PARA LA VECTORIZACION Y LIBERACION SELECTI... 85K€ Cerrado

ChemoBOOM Development of Palladium Labile Prodrugs for Bioorthogonally... 183K€ Cerrado

METBIOCAT Metal catalysis in biological habitats New strategies for o... 2M€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2017-08-17
Fecha Fin: 2023-08-31

Líder del proyecto

UNIVERSIDAD DE ZARAGOZA. OFICINA DE TRANSFERE... No se ha especificado una descripción o un objeto social para esta compañía.

Sin perfil tecnológico

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite intense research efforts in almost every branch of the natural sciences, cancer continues to be one of the leading causes of death worldwide. It is thus remarkable that little or no therapeutic use has been made of a whole discipline, heterogeneous catalysis, which is noted for its specificity and for enabling chemical reactions in otherwise passive environments. At least in part, this could be attributed to practical difficulties: the selective delivery of a catalyst to a tumour and the remote activation of its catalytic function only after it has reached its target are highly challenging objectives. Only recently, the necessary tools to overcome these problems seem within reach. CADENCE aims for a breakthrough in cancer therapy by developing a new therapeutic concept. The central hypothesis is that a growing tumour can be treated as a special type of reactor in which reaction conditions can be tailored to achieve two objectives: i) molecules essential to tumour growth are locally depleted and ii) toxic, short-lived products are generated in situ. To implement this novel approach we will make use of core concepts of reactor engineering (kinetics, heat and mass transfer, catalyst design), as well as of ideas borrowed from other areas, mainly those of bio-orthogonal chemistry and controlled drug delivery. We will explore two different strategies (classical EPR effect and stem cells as Trojan Horses) to deliver optimized catalysts to the tumour. Once the catalysts have reached the tumour they will be remotely activated using near-infrared (NIR) light, that affords the highest penetration into body tissues. This is an ambitious project, addressing all the key steps from catalyst design to in vivo studies. Given the novel perspective provided by CADENCE, even partial success in any of the approaches to be tested would have a significant impact on the therapeutic toolbox available to treat cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores